Previous 10 | Next 10 |
2023-10-27 13:30:18 ET MiMedx Group ( NASDAQ: MDXG ) is scheduled to announce Q3 earnings results on Monday, October 30th, after market close. The consensus EPS Estimate is $0.04 and the consensus Revenue Estimate is $78.12M (+15.4% Y/Y). For further details see: ...
2023-10-27 10:02:45 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...
MARIETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2023 after the market close on Monday, Octob...
2023-10-04 05:43:37 ET Summary MiMedx had strong Q2 2023 performance, particularly in Wound & Surgical; operational efficiency achieved but concerns over disbanding Regenerative Health division. Balance sheet healthy; liquidity robust but market signals caution with equity dil...
MARIETTA, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its portfolio of AWC solutions. EPIEFFECT expands the Company&...
YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a research collaboration agreement with MIMEDX Group, Inc (Nasdaq: ...
2023-08-01 18:48:03 ET MiMedx Group, Inc. (MDXG) Q2 2023 Earnings Conference Call August 01, 2023 05:00 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference...
2023-08-01 16:19:28 ET MiMedx Group press release ( NASDAQ: MDXG ): Q2 GAAP EPS of $0.00 beats by $0.03 . Revenue of $81.3M (+21.6% Y/Y) beats by $6.47M . As a result of our progress to date, we are increasing guidance for our full-year 2023 net sales percentag...
Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer Management to Host Conference Call on Tuesday...
2023-07-31 17:35:53 ET MiMedx Group ( NASDAQ: MDXG ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, after market close. The consensus EPS Estimate is -$0.03 and the consensus Revenue Estimate is $74.83M (+11.9% Y/Y). For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first publication in the 5 th most-cited journal in the world MARIET...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 3...